Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1996-12-19
|
| pubmed:abstractText |
This study tested the capability of a single 42-microgram dose of inhaled salmeterol xinafoate, a long-acting beta 2-agonist, to protect against bronchoconstrictive effects of exposure to 0.75 ppm sulfur dioxide (SO2) during exercise, for up to 24 h. Ten SO2-responsive adult volunteers with stable asthma were studied under 4 conditions of drug pretreatment/exposure, administered in random order, double-blind: salmeterol/SO2, placebo/SO2, salmeterol/clean air, and placebo/clean air. Each subject underwent 10-min exposure/exercise challenges in a chamber 1, 12, 18, and 24 h after pretreatment. Exercise ventilation rates averaged 29 L/min. Response was measured as the decrement in FEV1 between preexposure and postexposure (lowest value within 30 min). After salmeterol, mean decrement post-SO2 was 7% at 1 h and 12% at 12 h. At 18 and 24 h after salmeterol, and at all times after placebo, mean decrements were 25 to 30%. After 18 and 24 h, salmeterol still improved base-line FEV1 relative to placebo, although improvement was not statistically significant at 24 h. Acute symptom increases accompanied FEV1 decrements. CONCLUSION: In our asthmatic subjects, pretreatment with salmeterol imparted clinically and statistically significant (p < 0.01) protection against bronchoconstriction induced by SO2/exercise for at least 12 h, and maintained an improvement in lung function for as much as 18 h.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/Air Pollutants,
http://linkedlifedata.com/resource/pubmed/chemical/Albuterol,
http://linkedlifedata.com/resource/pubmed/chemical/Bronchodilator Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Placebos,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfur Dioxide,
http://linkedlifedata.com/resource/pubmed/chemical/salmeterol
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0012-3692
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
110
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1229-35
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:8915226-Administration, Inhalation,
pubmed-meshheading:8915226-Adrenergic beta-Agonists,
pubmed-meshheading:8915226-Adult,
pubmed-meshheading:8915226-Air,
pubmed-meshheading:8915226-Air Pollutants,
pubmed-meshheading:8915226-Albuterol,
pubmed-meshheading:8915226-Asthma,
pubmed-meshheading:8915226-Bronchial Provocation Tests,
pubmed-meshheading:8915226-Bronchoconstriction,
pubmed-meshheading:8915226-Bronchodilator Agents,
pubmed-meshheading:8915226-Cross-Over Studies,
pubmed-meshheading:8915226-Double-Blind Method,
pubmed-meshheading:8915226-Environmental Exposure,
pubmed-meshheading:8915226-Female,
pubmed-meshheading:8915226-Follow-Up Studies,
pubmed-meshheading:8915226-Forced Expiratory Volume,
pubmed-meshheading:8915226-Humans,
pubmed-meshheading:8915226-Male,
pubmed-meshheading:8915226-Middle Aged,
pubmed-meshheading:8915226-Physical Exertion,
pubmed-meshheading:8915226-Placebos,
pubmed-meshheading:8915226-Respiration,
pubmed-meshheading:8915226-Sulfur Dioxide
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Effect of inhaled salmeterol on sulfur dioxide-induced bronchoconstriction in asthmatic subjects.
|
| pubmed:affiliation |
Environmental Health Service, Rancho Los Amigos Medical Center, Downey, Calif 90242, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|